New markets require more than a new label.
We help companies evaluate and develop opportunities to move human health products, technologies, and platforms into animal health, and animal health innovations into human health. The work starts with a disciplined question: what would have to be true for this opportunity to deserve investment?
A promising asset needs a credible next market.
An existing product, research asset, or scientific platform may have value in another species, indication, or market. That possibility has to survive scrutiny of the evidence, customer need, development burden, economics, and route to adoption.
What the work can include
- Asset and portfolio screening against unmet needs and competitive alternatives
- Evidence assessment and development-gap mapping with scientific and technical specialists
- Market selection, customer discovery, positioning, and adoption analysis
- High-level development, regulatory, and commercialization pathway coordination
- Licensing, partnering, and new-company options
- Commercial business cases, decision milestones, and investment-readiness materials
What we help put in place
- Prioritized opportunities and explicit go, hold, or stop criteria
- An evidence-to-market roadmap with dependencies and decision gates
- A commercial model and partner strategy grounded in the target market
The scope and deliverables are tailored to the mandate, company stage, and available evidence.
Translation works when the whole model travels.
Biological relevance, evidence requirements, clinical workflows, purchasing behavior, and economics can change across markets. We connect those questions early so the commercial plan reflects the development reality. Scientific, clinical, and regulatory decisions remain with the appropriate qualified specialists.
Strategy & growth
Make the choices that shape the next chapter: where to compete, what to prioritize, and how to turn opportunity into a practical plan.
Explore this practice